Year-In-Diabetes: Review of High Impact Studies, 2023

In the last year, several trials have been published that could significantly change our way of approaching and managing patients with diabetes. We see evidence that continues to support the benefits of new agents for type 2 diabetes, and we are learning more about data that inform how we manage diabetes-related comorbidities and type 1 diabetes. This session will provide a review of trials published within the last year that will influence and impact our management of patients with diabetes.

Year-In-Diabetes: Review of High Impact Studies, 2024

Meaghan Stumpf, MD

University of Virginia

Year-In-Diabetes: Review of High Impact Studies, 2024

Christine Burt Solorzano, MD

University of Virginia

Year-In-Diabetes: Review of High Impact Studies, 2024

Leonor Corsino, MD, MHS

Duke University